Terbinafine hydrochloride- Blueberry Therapeutics

Drug Profile

Terbinafine hydrochloride- Blueberry Therapeutics

Alternative Names: BB-2603

Latest Information Update: 16 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Blueberry Therapeutics
  • Class Peptide aptamers
  • Mechanism of Action Protein folding inhibitors; Protein-protein interaction inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Onychomycosis; Tinea pedis

Most Recent Events

  • 29 Dec 2016 Phase-I/II clinical trials in Onychomycosis and Tinea pedis in Germany (Topical) (EudraCT2016-001242-25)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top